Skip to main content
. Author manuscript; available in PMC: 2024 Sep 4.
Published in final edited form as: Cancer Immunol Res. 2024 Mar 4;12(3):350–362. doi: 10.1158/2326-6066.CIR-23-0496

Fig. 2∣. Galectin-4 activates LILRB3 in a site-specific manner.

Fig. 2∣

(a) Percentages of indicated LILRB reporter cells activated by K562-Vec or K562-HLA-G cells. (b-c) Percentages of LILRB3 (b) or LILRB4 (c) reporter cells activated on recombinant coated ApoE or coated anti-LILRB3 (20 μg/mL). (d-h) Percentages of LILRB1 (d), LILRB2 (e), LILRB3 (f), LILRB4 (g), or LILRB5 (h) reporter cells activated on coated galectins (20 μg/mL). (i) Summary of LILRB reporter cells activated on coated galectins. (j) Percentages of LILRB3 reporter cells activated on coated or soluble galectin-4 or galectin-7 (20 μg/mL). (k) Percentages of LILRB31-443 or LILRB31-419 reporter cells activated on coated galectin-4 or anti-LILRB3 (20 μg/mL). Three technical replicates were performed for each condition and at least two independent experiments were performed for each condition. Error bars represent SEM and * indicates two-tailed student’s t-test p < 0.05.